Atropos Health and Every Cure partner to advance the discovery and development of therapies for underserved populations leveraging real-world data

New collaboration will see Every Cure leverage Atropos Health’s real-world evidence generation suite to confirm drug repurposing opportunities and speed their clinical development with real-world data trial emulation.  

Atropos Health, a known for its expertise in personalized real-world evidence (RWE), and Every Cure, a non-profit organization focused on exploring the full potential of existing medicines, have announced they began a collaboration in 2023 to develop a real-world data (RWD) driven approach to uncovering new uses for existing drugs. Within the partnership, Every Cure will leverage the vast Atropos Evidence™ Network of RWD and their GENEVA OS™ operating system for rapid RWE generation to verify and further examine the real-world signals coming from Every Cure’s own artificial-intelligence (AI) platform that suggest the potential of certain drugs to be repurposed for new indications.  

“Finding new uses for existing drugs is the fastest way to relieve the suffering of patients struggling with diseases with no existing treatments,” said Grant Mitchell, CEO and Co-Founder of Every Cure. “We are thrilled to partner with Atropos Health to rapidly validate the predictions made from Every Cure’s artificial intelligence engine and bring new treatments to patients. Additionally, Atropos Health and Geneva OS enables Every Cure to bolster the accuracy of our predictions by finding previously unseen connections between drug and disease found in real world data.” 

Every Cure’s AI-powered data engine approach to discovering and developing new treatment opportunities from existing medicines is significantly bolstered and accelerated through its integration with Atropos’ rapid, high quality evidence generation. In addition to real-world verification of Every Cure’s most promising drug-disease match signals, the CRAFT (Clinical Research Acceleration for Trials) Emulation Toolkit™ component of Atropos GENEVA OS enables modelling of the effect of therapies in real-world populations. This can accelerate clinical development through providing a real-world signal of patient response and ultimately speed patient access to effective therapies. 

“Producing high quality evidence from real-world data to confirm basic science hypotheses represents a major accelerant to drug repurposing,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “With Geneva OS and access to the Atropos Evidence Network Every Cure can accelerate evidence generation for drug repurposing in underserved populations.” 

This use case of GENEVA OS technology was recently highlighted in a Cell publication: Dylan Dodd of Stanford University leveraged Atropos Health to confirm a bench research finding that the antibiotic Bactrim could affect symptoms of the immune condition gout by shifting gut bacteria populations. Atropos Health produced RWE studies in deidentified patient populations that confirmed Dodd’s bench research findings and demonstrated the effect on coincident administration of Bactrim in existing gout populations. 

“The collaboration with Atropos Health adds a critical input to our AI platform for identifying new treatment opportunities from existing medicines,” said David Fajgenbaum, Cofounder and President of Every Cure. “By utilizing Atropos’ real-world evidence, we can discover new treatment opportunities, confirm bioinformatic-based predictions, and generate the evidence needed to drive therapies rapidly into clinical use.”